



JOHNS HOPKINS
M E D I C I N E

JOHNS HOPKINS
HEALTH SYSTEM

Promoting Interprofessional Collaboration by Developing an Enhanced Recovery After Surgery Program in Surgical Oncology

Brenda Smith Nettles, MS, DNP, ACNP-BC

Objectives and Disclosures

❖ Objectives

- Explain the phases of patient care included in the enhanced recovery after surgery (ERAS) protocol
- Review the multidisciplinary team required for ERAS
- Discuss the key elements of patient care for ERAS
- Describe the protocol developed for Surgical Oncology

❖ Brenda Smith Nettles has no conflicts of interest to disclose.

Enhanced Recovery After Surgery

❖ Evidence-based Perioperative Protocol

- Preadmission
- Preoperative
- Intraoperative
- Postoperative

Multidisciplinary Care Team

- ❖ **Surgical Oncologist**
- ❖ **Medical Oncologist**
- ❖ **Advanced Practice Providers**
- ❖ **Anesthesia Team**
- ❖ **ERAS Coordinator**
- ❖ **Nursing Staff**
- ❖ **Patient**

Key Elements of ERAS

- ❖ **Comprehensive Patient Education**
- ❖ **Preservation of Gastrointestinal Function**
- ❖ **Reduction in Organ Dysfunction**
- ❖ **Active Symptom Management**
- ❖ **Early Ambulation**

Cytoreduction & Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

❖ Patient Selection

- Primary Tumor
 - Appendix
 - Colon
 - Ovaries
 - Stomach
 - Unknown

❖ Clinical Staging

- Diagnostic Imaging
- Pathology Review





Cytoreduction & Hyperthermic Intraperitoneal Chemotherapy

❖ Cytoreduction (CRS)

- Surgical removal of visible disease
- Peritoneal Cancer Index
- Completeness of Cytoreduction score

❖ HIPEC Procedure

- Treatment for microscopic disease
- Delivery of heated chemotherapy into the abdomen
- Reconstruction

	Regions	Lesion Size	Lesion Size Score
	<ul style="list-style-type: none"> 0 Central 1 Right Upper 2 Epigastrium 3 Left Upper 4 Left Flank 5 Left Lower 6 Pelvis 7 Right Lower 8 Right Flank 9 Upper Jejunum 10 Lower Jejunum 11 Upper Ileum 12 Lower Ileum 		<ul style="list-style-type: none"> LS 0 No tumor seen LS 1 Tumor up to 0.5 cm LS 2 Tumor up to 5.0 cm LS 3 Tumor > 5.0 cm or confluence
PCI			

<http://www.hipec.com/knowledge-base/determining-the-peritoneal-cancer-index/>

Extended Recovery After HIPEC

❖ Decreased GI Motility

- Bowel changes
- Altered Absorption
- Weight Loss

❖ Decreased Activity Tolerance

- Anxiety
- Fatigue
- Postoperative Pain

Postoperative Complications

❖ Common Reasons for Readmission

- Inadequate pain control
- Intra-abdominal abscess
- Dehydration or malnutrition
- Pulmonary embolism or deep vein thrombosis
- Bowel obstruction
- Superficial wound infection

Interprofessional Collaboration



ERAS Protocol Review Process

❖ Committee Reviews

- Quality Improvement Committee
 - Approval of ERAS clinical pathway
- Clinical Practice Committee
 - Approval of electronic order sets
- Patient Education Committee
 - Approval of ERAS education booklets
 - Distribution of education videos

ERAS Clinical Pathway

❖ Establish Defined Goals for Discharge

- Nutrition
- Activity
- Pain Control
- Complication Management

Order Sets

❖ Preadmission

- Medical optimization
- Gastrointestinal bowel preparation
- Antibiotic prophylaxis
- Antimicrobial skin preparation
- Preoperative oral hydration

Order Sets

- ❖ **Intraperitoneal Chemotherapy**
 - Drug selection
 - HIPEC dose calculation
 - Premedication
 - Chemotherapy treatment plan

Order Sets

❖ Perioperative Patient Care

- Laboratory tests
- Medications
- Nursing Care
- Activity
- Nutrition
- Consultations

Patient Education

- ❖ Medications
- ❖ Nutrition
- ❖ Activity
- ❖ Pain Control

Evaluation of Clinical Outcomes

- ❖ **Decreased Recovery Times**
- ❖ **Shortened Hospital Stays**
- ❖ **Reduction in Cost of Care**
- ❖ **Increased Patient Satisfaction**

References

- Dreznik, Y., Hoffman, A., Hamburger, T., Ben-Yaacov, A., Dux, Y., Jacoby, H., ...Gutman, M. (2018). Hospital Readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies. *The Surgeon, 16*, 278-282.
- Martin, A., Abbott, D., Hanseman, D., Sussman, J., Kenkel, A., Greiwe, P., ... Ahmed, S. (2016). Factors associated with readmission after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis, *Annals of Surgical Oncology, 23*, 1941-1947.

References

Pedziwiatr, M., Mavrikis, J., Witowski, J., Adamos, A., Major, P., & Budyzynski, A. (2018). Current status of enhanced recovery after surgery (ERAS) protocol in gastrointestinal surgery. *Medical Oncology*, 35, 95.